Source: GlobalData
Diagnosed prevalent cases of prostate cancer across 8MM to reach 4.24 million in 2033, forecasts GlobalData
Posted in Pharma
The burden of five-year diagnosed prevalent cases of prostate cancer is expected to increase at an annual growth rate (AGR) of 3.10% from around 3.23 million in 2023 to 4.24 million in 2033 across the eight major markets (8MM*), forecasts GlobalData, a leading data and analytics company.
GlobalData’s latest report, “Prostate Cancer: Epidemiology Forecast to 2033,” reveals that the increase is partly attributed to the increased survival rate of prostate cancer patients due to modern medicine, combined with underlying demographic changes in the respective markets.
The prevalence of prostate cancer is known to vary depending on the market region. According to GlobalData epidemiologists, the US had the highest number of five-year diagnosed prevalent cases of prostate cancer in 2023 with 1.11 million cases, whereas Spain had the lowest number of prevalent cases at 128,000.
Bishal Bhandari, PhD, Associate Director of Epidemiology at GlobalData, comments: “The growth of the five-year diagnosed prevalent cases of prostate cancer in the 8MM is the result of longer life expectancy and an increase in the incidence of the disease. The patient survivals are also steadily rising, due to improved prevention, early diagnosis, and treatment. In 2023, only 25% of the diagnosed prevalent cases of prostate cancer in the 8MM were in advanced stages.”
GlobalData epidemiologists also observed an age difference in prostate cancer. The biggest risk factor for prostate cancer is advancing age. This forecast reflects the burden in older men; in 2023, more than 85% of cases occurred in men ages 60 years and older. Only 1% of cases occurred in men younger than age 50 years.
Bhandari concludes: “A major factor that will impact the epidemiology of prostate cancer cases in the coming years will be the role of prostate-specific antigen (PSA) testing for prostate cancer screening. PSA screening can detect prostate cancer early, but it can also result in the detection of non-life-threatening tumors, causing unnecessary anxieties. Therefore, PSA screening guidelines vary between countries and have changed over time. Future changes in PSA screening guidelines would likely have a major impact on the diagnosis of prostate cancer cases.”
*8MM: The US, France, Germany, Italy, Spain, the UK, Japan, and China